Axsome Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update
May 08, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
Clinical successes highlight Axsome’s accelerated evolution into a leading CNS company Positive pivotal Phase 2/3 results for AXS-05 in Alzheimer’s disease agitation further deepen innovative...
Aptinyx Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
March 30, 2020 16:01 ET
|
Aptinyx Inc.
Initiated four Phase 2 clinical studies based on compelling prior data Actions taken on ongoing clinical studies due to COVID-19 pandemic Strong cash position following recently completed common...
Aptinyx to Report Fourth Quarter and Full Year 2019 Financial Results on Monday, March 30, 2020
March 18, 2020 16:01 ET
|
Aptinyx Inc.
EVANSTON, Ill., March 18, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Aptinyx to Present at Upcoming Investor Conferences
February 19, 2020 08:37 ET
|
Aptinyx Inc.
EVANSTON, Ill., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer’s Reboxetine Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate
January 13, 2020 06:00 ET
|
Axsome Therapeutics, Inc.
Agreement accelerates ongoing clinical development of AXS-12 (reboxetine) in narcolepsy Expands Axsome’s pipeline with new Phase 3-stage esreboxetine product candidate for fibromyalgia ...
Aptinyx to Present at 38th Annual J.P. Morgan Healthcare Conference
December 12, 2019 07:07 ET
|
Aptinyx Inc.
EVANSTON, Ill., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Aptinyx to Present at Upcoming Investor Conferences
November 14, 2019 07:57 ET
|
Aptinyx Inc.
EVANSTON, Ill., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Aptinyx Reports Third Quarter 2019 Financial Results and Highlights
November 12, 2019 16:01 ET
|
Aptinyx Inc.
Initiated two Phase 2 studies of NYX-2925 in chronic pain conditions On track to have four Phase 2 studies ongoing by year end across pipeline of CNS product candidates Conference call today at 5:00...
Aptinyx Initiates Two Phase 2 Studies of NYX-2925 in Patients with Chronic Centralized Pain Conditions
November 12, 2019 07:27 ET
|
Aptinyx Inc.
200-patient painful diabetic peripheral neuropathy study and 300-patient fibromyalgia study build on previous compelling data obtained in these indications Top-line efficacy and safety data...
Aptinyx to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019
November 05, 2019 08:07 ET
|
Aptinyx Inc.
EVANSTON, Ill., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...